Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of “Moderate Buy” by Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $19.86.

HIMS has been the subject of several analyst reports. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company. TD Cowen boosted their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Truist Financial raised their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Bank of America lowered their price target on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th.

Insider Activity

In related news, insider Michael Chi sold 9,313 shares of Hims & Hers Health stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $22.00, for a total value of $204,886.00. Following the completion of the sale, the insider now directly owns 185,326 shares in the company, valued at approximately $4,077,172. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Hims & Hers Health news, insider Michael Chi sold 9,313 shares of the company’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $22.00, for a total value of $204,886.00. Following the completion of the sale, the insider now owns 185,326 shares in the company, valued at $4,077,172. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $551,777.94. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 542,585 shares of company stock worth $8,751,851. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Hims & Hers Health by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after buying an additional 193,507 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after buying an additional 1,634,000 shares during the period. Finally, Verition Fund Management LLC grew its holdings in shares of Hims & Hers Health by 30.9% during the 4th quarter. Verition Fund Management LLC now owns 798,660 shares of the company’s stock worth $7,108,000 after purchasing an additional 188,506 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 4.9 %

Shares of HIMS stock opened at $19.32 on Wednesday. The firm’s fifty day moving average price is $16.82 and its two-hundred day moving average price is $17.25. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $25.74. The firm has a market capitalization of $4.15 billion, a P/E ratio of -1,931.50 and a beta of 1.05.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the previous year, the business earned ($0.03) earnings per share. Hims & Hers Health’s quarterly revenue was up 51.8% on a year-over-year basis. As a group, equities research analysts forecast that Hims & Hers Health will post 0.22 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.